Impact Biomedical (IBO) Cash from Financing Activities (2022 - 2026)
Impact Biomedical's (IBO) quarterly Cash from Financing Activities came in at $482000.0 in Q1 2026, up 52.05% on a QoQ basis from $317000.0 in Q4 2024.
Impact Biomedical (IBO) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 4 years of Cash from Financing Activities data on file, last reported at $482000.0 in Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $482000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (changed N/A YoY) and the FY2025 annual result came in at -$109000.0, down 102.25% from the prior year.
- Cash from Financing Activities improved to $482000.0 in Q1 2026, from $317000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $3.7 million in Q3 2024 to a low of $232000.0 in Q4 2023.
- A 4-year average of $864454.5 and a median of $539000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 56.96% — and 2024, when it jumped 321.38%.
- Tracing IBO's Cash from Financing Activities over 4 years: stood at $539000.0 in 2022, then slumped by 56.96% to $232000.0 in 2023, then surged by 36.64% to $317000.0 in 2024, then surged by 52.05% to $482000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $482000.0 (Q1 2026), $317000.0 (Q4 2024), and $3.7 million (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 482,000.00 |
| Mar 31, 2026 | 482,000.00 |
| Dec 31, 2024 | 317,000.00 |
| Dec 31, 2024 | 317,000.00 |
| Sep 30, 2024 | 3.67 Mn |
| Sep 30, 2024 | 3.67 Mn |
| Jun 30, 2024 | 384,000.00 |
| Jun 30, 2024 | 384,000.00 |
| Mar 31, 2024 | 483,000.00 |
| Mar 31, 2024 | 483,000.00 |
| Dec 31, 2023 | 232,000.00 |
| Dec 31, 2023 | 232,000.00 |
| Sep 30, 2023 | 870,000.00 |
| Sep 30, 2023 | 870,000.00 |
| Jun 30, 2023 | 746,000.00 |
| Jun 30, 2023 | 746,000.00 |
| Mar 31, 2023 | 1.02 Mn |
| Mar 31, 2023 | 1.02 Mn |
| Dec 31, 2022 | 539,000.00 |
| Dec 31, 2022 | 539,000.00 |